HU-331 is a catalytic inhibitor of topoisomerase IIα

Chemical Research in Toxicology

Volumn 27, Issue 12, 2014, Pages 2044-2051

  Regal, Kellie M ^a   Mercer, Susan L ^a,b   Deweese, Joseph E ^a,b  

^a LIPSCOMB UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DITHIOTHREITOL; DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR; HU 331; QUINONE DERIVATIVE; TOPOISOMERASE II ALPHA; UNCLASSIFIED DRUG;

ARTICLE; ATPASE ACTIVITY ASSAY; CONTROLLED STUDY; DNA BINDING; DNA CLEAVAGE; DNA STRAND BREAKAGE; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVITY; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; HYDROLYSIS; IN VITRO STUDY; NONHUMAN; THIN LAYER CHROMATOGRAPHY;

EID: 84918563534     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx500245m     Document Type: Article

References (61)

1. Kanaar, R., and Cozzarelli, N. R. (1992) Roles of supercoiled DNA structure in DNA transactions. Curr. Opin. Struct. Biol. 2, 369-379.
2. Wang, J. C. (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 3, 430-440.
3. Bates, A. D., and Maxwell, A. (2005) DNA Topology, Oxford University Press, New York.
4. McClendon, A. K., and Osheroff, N. (2007) DNA topoisomerase II, genotoxicity, and cancer. Mutat. Res. 623, 83-97.
5. Falaschi, A., Abdurashidova, G., Sandoval, O., Radulescu, S., Biamonti, G., and Riva, S. (2007) Molecular and structural transactions at human DNA replication origins. Cell Cycle 6, 1705-1712.
6. Nitiss, J. L. (1998) Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim. Biophys. Acta 1400, 63-81.
7. Deweese, J. E., Osheroff, M. A., and Osheroff, N. (2009) DNA topology and topoisomerases: teaching a "knotty" subject. Biochem. Mol. Biol. Educ. 37, 2-10.
8. Gibson, E. G., and Deweese, J. E. (2013) Covalent poisons of topoisomerase II. Curr. Top. Pharmacol. 17, 1-12.
9. Osheroff, N. (1987) Role of the divalent cation in topoisomerase II mediated reactions. Biochemistry 26, 6402-6406.
10. Zechiedrich, E. L., and Osheroff, N. (1990) Eukaryotic topoisomerases recognize nucleic acid topology by preferentially interacting with DNA crossovers. EMBO J. 9, 4555-4562.
11. Roca, J., Berger, J. M., and Wang, J. C. (1993) On the simultaneous binding of eukaryotic DNA topoisomerase II to a pair of double-stranded DNA helices. J. Biol. Chem. 268, 14250-14255.
12. Schmidt, B. H., Burgin, A. B., Deweese, J. E., Osheroff, N., and Berger, J. M. (2010) A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases. Nature 465, 641-644.
13. Liu, L. F., Rowe, T. C., Yang, L., Tewey, K. M., and Chen, G. L. (1983) Cleavage of DNA by mammalian DNA topoisomerase II. J. Biol. Chem. 258, 15365-15370.
14. Zechiedrich, E. L., Christiansen, K., Andersen, A. H., Westergaard, O., and Osheroff, N. (1989) Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate. Biochemistry 28, 6229-6236.
15. Mueller-Planitz, F., and Herschlag, D. (2008) Coupling between ATP binding and DNA cleavage by DNA topoisomerase II: a unifying kinetic and structural mechanism. J. Biol. Chem. 283, 17463-17476.
16. Deweese, J. E., and Osheroff, N. (2009) Coordinating the two protomer active sites of human topoisomerase II: nicks as topoisomerase II poisons. Biochemistry 48, 1439-1441.
17. Deweese, J. E., and Osheroff, N. (2010) The use of divalent metal ions by type II topoisomerases. Metallomics 2, 450-459.
18. Schmidt, B. H., Osheroff, N., and Berger, J. M. (2012) Structure of a topoisomerase II-DNA-nucleotide complex reveals a new control mechanism for ATPase activity. Nat. Struct. Mol. Biol. 19, 1147-1154.
19. Lindsley, J. E., and Wang, J. C. (1993) On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II. J. Biol. Chem. 268, 8096-8104.
20. Classen, S., Olland, S., and Berger, J. M. (2003) Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc. Natl. Acad. Sci. U.S.A. 100, 10629-10634.
21. Wei, H., Ruthenburg, A. J., Bechis, S. K., and Verdine, G. L. (2005) Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase. J. Biol. Chem. 280, 37041-37047.
22. Bendsen, S., Oestergaard, V. H., Skouboe, C., Brinch, M., Knudsen, B. R., and Andersen, A. H. (2009) The QTK loop is essential for the communication between the N-terminal ATPase domain and the central cleavage - ligation region in human topoisomerase IIalpha. Biochemistry 48, 6508-6515.
23. Osheroff, N. (1986) Eukaryotic topoisomerase II. Characterization of enzyme turnover. J. Biol. Chem. 261, 9944-9950.
24. Osheroff, N., and Zechiedrich, E. L. (1987) Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: trapping the covalent enzyme-DNA complex in an active form. Biochemistry 26, 4303-4309.
25. Robinson, M. J., and Osheroff, N. (1991) Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry 30, 1807-1813.
26. Bromberg, K. D., Hendricks, C., Burgin, A. B., and Osheroff, N. (2002) Human topoisomerase IIalpha possesses an intrinsic nucleic acid specificity for DNA ligation. Use of 5′ covalently activated oligonucleotide substrates to study enzyme mechanism. J. Biol. Chem. 277, 31201-31206.
27. Roca, J., and Wang, J. C. (1992) The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases. Cell 71, 833-840.
28. Harkins, T. T., Lewis, T. J., and Lindsley, J. E. (1998) Pre-steady-state analysis of ATP hydrolysis by Saccharomyces cerevisiae DNA topoisomerase II. 2. Kinetic mechanism for the sequential hydrolysis of two ATP. Biochemistry 37, 7299-7312.
29. Nitiss, J. L. (2009) DNA topoisomerase II and its growing repertoire of biological functions. Nat. Rev. Cancer 9, 327-337.
30. Drake, F. H., Zimmerman, J. P., McCabe, F. L., Bartus, H. F., Per, S. R., Sullivan, D. M., and Crooke, S. T. (1987) Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J. Biol. Chem. 262, 16739-16747.
31. Tsai-Pflugfelder, M., Liu, L. F., Liu, A. A., Tewey, K. M., Whang-Peng, J., Knutsen, T., and Wang, J. C. (1988) Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc. Natl. Acad. Sci. U.S.A. 85, 7177-7181.
32. Drake, F. H., Hofmann, G. A., Bartus, H. F., Mattern, M. R., Crooke, S. T., and Mirabelli, C. K. (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28, 8154-8160.
33. Chung, T. D., Drake, F. H., Tan, K. B., Per, S. R., Crooke, S. T., and Mirabelli, C. K. (1989) Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc. Natl. Acad. Sci. U.S.A. 86, 9431-9435.
34. Austin, C. A., and Fisher, L. M. (1990) Isolation and characterization of a human cDNA clone encoding a novel DNA topoisomerase II homologue from HeLa cells. FEBS Lett. 266, 115-117.
35. Jenkins, J. R., Ayton, P., Jones, T., Davies, S. L., Simmons, D. L., Harris, A. L., and Hickson, I. D. (1992) Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res. 20, 5587-5592.
36. Tan, K. B., Dorman, T. E., Falls, K. M., Chung, T. D., Mirabelli, C. K., Crooke, S. T., and Mao, J. (1992) Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res. 52 , 231-234.
37. Ju, B. G., Lunyak, V. V., Perissi, V., Garcia-Bassets, I., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (2006) A topoisomerase IIinnodatabeta- mediated dsDNA break required for regulated transcription. Science 312, 1798-1802.
38. Cowell, I. G., and Austin, C. A. (2012) Do transcription factories and TOP2B provide a recipe for chromosome translocations in therapy-related leukemia? Cell Cycle 11, 3143-3144.
39. Cowell, I. G., and Austin, C. A. (2012) Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents. Int. J. Environ. Res. Public Health 9, 2075-2091.
40. Cowell, I. G., Sondka, Z., Smith, K., Lee, K. C., Manville, C. M., Sidorczuk-Lesthuruge, M., and Austin, C. A. (2012) Model for MLL translocations in therapy-related leukemia involving topoisomerase IIbeta-mediated DNA strand breaks and gene proximity. Proc. Natl. Acad. Sci. U.S.A. 109, 8989-8994.
41. Champoux, J. J. (2001) DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70, 369-413.
42. Deweese, J. E., and Osheroff, N. (2009) The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res. 37 , 738-749.
43. Osheroff, N. (1998) DNA topoisomerases. Biochim. Biophys. Acta 1400, 1-2.
44. Wilstermann, A. M., and Osheroff, N. (2003) Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr. Top. Med. Chem. 3, 321-338.
45. Nitiss, J. L. (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 9, 338-350.
46. Bender, R. P., and Osheroff, N. (2008) DNA topoisomerases as targets for the chemotherapeutic treatment of cancer, in Checkpoint Responses in Cancer Therapy (Dai, W., Ed.) pp 57-91, Humana Press, Totowa, NJ.
47. Felix, C. A. (2001) Leukemias related to treatment with DNA topoisomerase II inhibitors. Med. Pediatr. Oncol. 36, 525-535.
48. Felix, C. A., Kolaris, C. P., and Osheroff, N. (2006) Topoisomerase II and the etiology of chromosomal translocations. DNA Repair 5, 1093-1108.
49. Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L. S., Lyu, Y. L., Liu, L. F., and Yeh, E. T. (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639-1642.
50. Kogan, N. M., Rabinowitz, R., Levi, P., Gibson, D., Sandor, P., Schlesinger, M., and Mechoulam, R. (2004) Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J. Med. Chem. 47, 3800-3806.
51. Kogan, N. M., Schlesinger, M., Peters, M., Marincheva, G., Beeri, R., and Mechoulam, R. (2007) A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study. J. Pharmacol. Exp. Ther. 322, 646-653.
52. Kogan, N. M., Schlesinger, M., Priel, E., Rabinowitz, R., Berenshtein, E., Chevion, M., and Mechoulam, R. (2007) HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. Mol. Cancer Ther. 6, 173-183.
53. Peters, M., and Kogan, N. M. (2007) HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity. Expert Opin. Invest. Drugs 16, 1405-1413.
54. Wu, H. Y., and Jan, T. R. (2010) Cannabidiol hydroxyquinoneinduced apoptosis of splenocytes is mediated predominantly by thiol depletion. Toxicol. Lett. 195, 68-74.
55. Usami, N., Yamamoto, I., and Watanabe, K. (2008) Generation of reactive oxygen species during mouse hepatic microsomal metabolism of cannabidiol and cannabidiol hydroxy-quinone. Life Sci. 83, 717-724.
56. Oestergaard, V. H., Bjergbaek, L., Skouboe, C., Giangiacomo, L., Knudsen, B. R., and Andersen, A. H. (2004) The transducer domain is important for clamp operation in human DNA topoisomerase IIalpha. J. Biol. Chem. 279, 1684-1691.
57. Biersack, H., Jensen, S., Gromova, I., Nielsen, I., Westergaard, O., and Andersen, A. (1996) Active heterodimers are formed from human DNA topoisomerase IIa and IIb isoforms. Proc. Natl. Acad. Sci. U.S.A. 93, 8288-8293.
58. Fortune, J. M., and Osheroff, N. (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIa by blocking DNA cleavage. J. Biol. Chem. 273, 17643-17650.
59. Jacob, D. A., Mercer, S. L., Osheroff, N., and Deweese, J. E. (2011) Etoposide quinone is a redox-dependent topoisomerase II poison. Biochemistry 50, 5660-5667.
60. Jacob, D. A., Gibson, E. G., Mercer, S. L., and Deweese, J. E. (2013) Etoposide catechol is an oxidizable topoisomerase II poison. Chem. Res. Toxicol. 26, 1156-1158.
61. Bender, R. P., Ham, A. J., and Osheroff, N. (2007) Quinoneinduced enhancement of DNA cleavage by human topoisomerase IIinnodataalpha: adduction of cysteine residues 392 and 405. Biochemistry 46, 2856-2864.